A randomized double-blind placebo-controlled study with ASA treatment in colorectal cancer patients with mutations in the PI3K signaling pathway

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513778-23-00

Enrollment

700

Registered

2024-10-01

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon and rectal cancer tumor stage II-III, PIK3R1 or PTEN, tumor with somatic alterationsin PIK3CA

Brief summary

• TTR at 3 years, in patients with tumors harboring PIK3CA mutations in exon 9 and 20

Interventions

DRUGThe placebo tablet composition is: Collodial silicone dioxide

DRUGMagnesium stearate

DRUGCarmellose sodium

DRUGCellulosa powder. Appearance and size will be the same for active and placebo.

DRUGTrombyl 160 mg tabletter

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
• TTR at 3 years, in patients with tumors harboring PIK3CA mutations in exon 9 and 20	—

Countries

Denmark, Finland, Norway, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026